Skip to content

A randomised study of the postoperative quality of life: laparoscopic UTerine Artery Clipping versus laparoscopy-assisted vaginal hysterectomy for the management of symptomatic uterine fibroids

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN76790866
Enrollment
60
Registered
2007-06-25
Start date
2007-05-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine fibroids Urological and Genital Diseases Other noninflammatory disorders of uterus, except cervix

Interventions

Group 1: treated with Laparoscopic Uterine Artery Clipping (LUAC) Group 2: treated with Laparoscopy-Assisted Vaginal Hysterectomy (LAVH) After both treatments, we will follow up the enrolled patients

Sponsors

Seoul National University (South Korea)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Aged greater than or equal to 40 years old 2. Patients who do not want conception any more 3. Patients who agree to this study with informed consent 4. More than 2 cm sized uterine fibroids on Ultrasonography (USG) 5. Uterine fibroids with symptoms such as menorrhagia, dysmenorrhoea, lower abdominal discomfort or pain, lower back pain, urologic problems (dysuria, frequency, etc.,) 6. Patients without underlying disease affecting QOL 7. At least six months interval after last medication, if patients have been treated with Gonadotropin-Releasing Hormone (GnRH) agonists

Exclusion criteria

Exclusion criteria: 1. Aged less than 40 years old 2. Patients with subserosal pedunculated fibroid 3. Pregnant women 4. Patients with pelvic inflammatory disease developed within one month 5. Patients with contraindication of surgical treatment 6. Patients with previous history of myomectomy, hysterectomy, myolysis, uterine artery embolisation 7. Less than six months interval after last medication, if patients have been treated with GnRH agonist 8. Patients with underlying disease affecting QOL

Design outcomes

Primary

MeasureTime frame
Postoperative quality of life until one year after surgical treatment using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) version 3.0.

Secondary

MeasureTime frame
1. Volume reduction of uterus, ovary, and fibroids in Group 1: Volume (cm^3) = length (cm) X width (cm) X depth (cm) X 0.5233, measured every three months till one year 2. Improvement of subjective symptoms in both groups: 11 point symptom score, ranging from -5 (markedly worse) to +5 (markedly better), checked after one year postoperatively 3. Evaluation of postoperative menorrhagia in Group 1: using a simple visual assessment technique, measured monthly using the recording sheet including simple visual assessment technique by herself. After one year postoperatively, we will collect the recording sheets from the patients and analyze the data.

Countries

Korea, South

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 3, 2026